For clarity, there are two separate Indian entities involved:

- Novartis India Limited (NIL) – listed on BSE (this is what ChrysCapital is buying into)

- Novartis Healthcare Private Limited (NHPL) – unlisted, 100% Novartis AG subsidiary (commercial arm, corporate centre, R&D)

1. What happens to the listed Novartis India Limited (NIL)?

Based on the announced deal and filings as of 20 February 2026:

1. Change in Promoter / Ownership

- Novartis AG will sell its entire 70.68% stake in NIL to a ChrysCapital–led consortium (WaveRise Investments, ChrysCapital Fund X, Two Infinity Partners and related entities). (novartis.com)

- After closing, Novartis AG will completely exit as promoter and the ChrysCapital consortium will become the new promoter group. (business-standard.com)

2. Mandatory Open Offer

- As per SEBI (SAST) Regulations, the acquirers have announced a mandatory open offer for 26% of NIL’s equity from public shareholders at ₹860.64 per share. (outlookbusiness.com)

- If fully subscribed, the consortium’s holding could go up to ~96.68%; if no one tenders, they remain at 70.68%. (business-standard.com)

Whether an individual shareholder tenders or not is a personal investment decision; the offer is optional for public shareholders.

3. Listing Status & Delisting

- The acquirers have explicitly stated that they do not intend to delist NIL and will ensure compliance with the minimum public shareholding norms if needed. (business-standard.com)

- Therefore, NIL is expected to remain a listed company on BSE under a new promoter group.

4. Name Change & Branding

- As part of the transaction, NIL has agreed to change its name and remove “Novartis” / seller‑group references within 120 days of closing, subject to regulatory and corporate approvals. (business-standard.com)

- Over time, you should expect:

- New company name

- Rebranding of the listed entity away from the global Novartis identity

5. Business Model & Operations

- Currently, NIL is primarily into wholesale distribution of pharmaceuticals and medical goods (marketing/legacy brands, not manufacturing). (business-standard.com)

- Post‑transaction, operations will continue, but:

- Strategic direction will be driven by the ChrysCapital‑led promoter group.

- Commercial arrangements (trademarks, distribution rights, etc.) with the Novartis group are contractual. Public disclosures so far do not specify any immediate change to these, so near‑term disruption is not indicated; however, such contracts can be renegotiated or evolve over time.

- Markets have reacted sharply: NIL hit the 20% upper circuit today on news of the promoter exit and open offer. (m.economictimes.com)

- Future share price performance, dividends, and business strategy will depend on what ChrysCapital does operationally – that cannot be predicted with certainty.

In essence for the listed company:

- Promoter changes from Novartis AG to a ChrysCapital‑led PE consortium.

- Company stays listed, but name and branding will change, with potential strategic repositioning over time.

---

2. What happens to the unlisted Novartis Healthcare Private Limited (NHPL)?

NHPL (often referred to as Novartis Healthcare) is not part of this stake sale.

From Novartis’ own release:

- NHPL is a wholly owned subsidiary of the Novartis group in India and includes:

- The commercial arm of Novartis in India

- The Novartis Corporate Center in Hyderabad

- R&D and clinical operations (clinical trials across >300 sites in India) (novartis.com)

- Novartis explicitly states that:

- NIL (listed) is separate from NHPL (unlisted), and

- The transfer of Novartis AG’s stake in NIL “will not impact Novartis Healthcare Private Limited operations.” (novartis.com)

In essence for NHPL:

- Remains unlisted and remains part of the Novartis AG group.

- Ownership and control stay with Novartis AG.

- Operational focus on innovative medicines, commercial operations and R&D in India continues as before, aligned with Novartis’ global pure‑play innovative medicines strategy. (novartis.com)

There is no announced IPO, listing plan, or sale of NHPL as of today’s disclosures.

---

3. Conceptual summary for an investor

- The listed Novartis India Limited you trade on BSE will effectively become a ChrysCapital‑controlled, rebranded pharma distribution/marketing platform in India, still listed, with a very high promoter holding post‑offer.

- The unlisted Novartis Healthcare Pvt Ltd remains 100% Novartis AG, continuing as the MNC’s India hub for commercial and R&D activities – this entity is not directly investible on exchanges at present.

Any decision to:

- tender shares into the open offer, or

- continue holding the rebranded, PE‑controlled listed company

must be based on your own risk profile, return expectations, and view on how the new promoters will manage the business. This is informational and not individual investment advice.

---

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com